Immuno Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Immuno Technologies is a privately held, preclinical biotech company advancing a novel intranasal, viral-vector based vaccine for Lyme disease, branded as LymeMist™, alongside diagnostic assays. The company operates on a capital-efficient model, leveraging SBIR grant funding to de-risk its programs up to the pre-IND stage before seeking strategic licensing partnerships for commercialization. With an estimated 476,000 annual cases in the U.S., the lack of a marketed human Lyme disease vaccine presents a significant unmet medical need and commercial opportunity for ITi's lead candidate.

Infectious DiseaseVector-Borne Diseases

Technology Platform

Parainfluenza 5 (PIV5) viral vector platform for intranasal vaccine delivery, coupled with modified antigen design (e.g., OspA for Lyme). Additional platform for point-of-care diagnostic assay development.

Opportunities

The lack of an approved human Lyme disease vaccine in the U.S., coupled with an estimated 476,000 annual cases, presents a massive unmet need and commercial opportunity.

ITi's intranasal, needle-free approach could offer superior compliance, durability, and ease of administration compared to injectable competitors, potentially capturing significant market share.

Risk Factors

The lead vaccine candidate is in preclinical development, with high risk of failure in future animal or human trials.

The company is heavily reliant on non-dilutive SBIR funding and has no commercial revenue.

Success depends entirely on securing a licensing partnership after generating pre-IND data.

Competitive Landscape

The Lyme vaccine space is competitive, with Pfizer/Valneva's VLA15 (injectable, Phase 3) as the most advanced candidate, though facing delays. Other biotechs are also pursuing OspA-based and other vaccine strategies. The diagnostic market has several established players, though room exists for improved point-of-care tests.

More companies in Biologics / Biosimilars →More companies in United States →